KDR and neoplasm: Cabozantinib is an inhibitor of VEGFR2, MET, and RET [684] that also binds to the ATP-binding site of RTKs [690], thereby inhibiting autophosphorylation of RTKs, which leads to tumor hypoxia and apoptosis and suppresses metastasis, angiogenesis, and tumor growth [684, 691].